Pethidine is the only member of the opioid family that has clinically important local anaesthetic activity in the dose range normally used for analgesia. Pethidine is unique as the only opioid in current use that is effective as the sole agent for spinal anaesthesia. In lower doses, intrathecal pethidine is also an effective analgesic for treating pain in labour. This paper reviews the pharmacology of intrathecal pethidine and clinical experience reported to date. Articles reviewed include those identified by a Medline search using keywords "intrathecal" or "spinal anaesthesia/ anesthesia" and "pethidine" or "meperidine". Reference lists from identified papers were scrutinized to identify further relevant articles.
HISTORY
Pethidine was the first synthetic opioid to be used to provide analgesia in humans. Shortly after its analgesic properties were discovered by Eisleb and Schaumann in 1939 1 , pethidine was shown also to have local anaesthetic activity comparable with that of cocaine 2 . Subsequently, pethidine has been investigated for a number of clinical applications, including peripheral nerve block, intravenous regional anaesthesia, and intrathecally for spinal anaesthesia and analgesia. Following initial reports in animals 3 , Cousins et al reported the use of intrathecal pethidine in doses of 10 to 30 mg to treat cancer pain in humans 4 . The first report of the use of pethidine as sole agent for spinal anaesthesia was published in the French literature by Mircea in 1982 5 and has been followed by a number of reports that have used pethidine alone and in combination with conventional local anaesthetics for spinal anaesthesia for a variety of different surgical procedures.
PHARMACOLOGY
Pethidine and its derivatives have similar physicochemical properties to conventional local anaesthetic drugs, with molecular weight and pKa in particular being closely related (Table 1) . Early investigations of the pharmacological properties of pethidine explained its analgesic and local anaesthetic properties on structural similarities to cocaine and morphine 1, 2 . A number of in vitro studies have confirmed the ability of phenylpiperidine opioids to block conduction in peripheral nerve 2, 6, 7 . Gissen et al found that fentanyl and sufentanil in high concentrations decreased the amplitude of action potentials after nerve stimulation 7 . This effect was not prevented by pretreatment with naloxone and is evidence that the effect of the phenylpiperidine derivatives on nerve conduction is independent of opioid receptors. Power et al showed that pethidine and fentanyl but not diamorphine blocked nerve conduction in a similar nerve preparation 6 . Pethidine at a concentration of 0.5 mg/ml blocked conduction completely and reversibly. Fentanyl also blocked nerve conduction at similar concentrations but these concentrations are much greater than the commercially available preparation.
The local anaesthetic activity of pethidine has been demonstrated in a number of in vivo investigations. Intradermal injection of pethidine 2% caused a decrease in sensory perception greater than that caused by saline and similar to that caused by lignocaine 0.5% 8 . Animal studies confirmed the ability of perineurally administered pethidine to block nerve conduction, and also showed motor and sensory block after subarachnoid and epidural administration that was comparable to that achieved with lignocaine 9 . In humans, Beyazova et al investigated the effect of perineural injection of pethidine in concentrations of 0.5 to 1.5 mg/ml on conduction in the sural nerve 10 . Concentrations of 1.0 and 1.5 mg/ml caused hypoalgesia and a significant reduction in the amplitude of sensory evoked responses. A concentration of 0.5 mg/ml also caused hypoalgesia but the reduction in nerve response amplitude seen did not reach statistical significance. Oldroyd et al injected pethidine intradermally in concentrations of 0.5, 1 and 2 mg/ml and found reduction of sharp sensation occurred with the higher two concentrations 11 . They followed this with injection of 40 ml of pethidine 1 to 2 mg/ml by an intravenous regional anaesthetic technique and found both concentrations caused complete loss of sharp sensation. Compared with prilocaine 0.5%, the onset of anaesthesia was slower and loss of touch sensation and motor block was less complete. In a similar study, Armstrong et al found that intravenous regional anaesthesia was enhanced by the addition of pethidine 100 mg to prilocaine 0.25% 12 . Acalovschi and Cristea found that intravenous regional anaesthesia using 40 ml pethidine 0.25% gave sensory block that was inferior to that from lignocaine 0.5% and was associated with more side-effects which precluded the authors from recommending pethidine as a sole agent for this technique 13 .
Intrathecal injection of pethidine produces spinal anaesthesia that is qualitatively similar to that achieved with conventional local anaesthetics. However, the exact mechanism by which this is achieved is controversial. Flanagan et al were unable to demonstrate measurable block of the median nerve in human volunteers using 5 ml pethidine 0.5% and 1.5% 14 and this group has suggested that mechanisms other than a simple inhibition of sodium currents may be responsible for the spinal anaesthesia associated with intrathecal pethidine 15 . Clinical reports of spinal anaesthesia using pethidine have used commercially available preparations which have a concentration of 50 mg/ml and are preservativefree. This solution has a specific gravity of 1.009 which is close to the upper limit of specific gravity of cerebrospinal fluid (CSF) and when injected intrathecally, pethidine has the properties of a hyperbaric agent 5 .
Several studies have measured concentrations of pethidine in plasma and CSF after intrathecal injection. Following a dose of 1 mg/kg, plasma concentrations of pethidine reached maximum mean levels (C max ) of 107-341 ng/ml [16] [17] [18] [19] which is less than the reported minimum effective analgesic concentration (MEAC) of 460 ng/ml 20 . Mean time to maximum concentration (t max ) varied from 45 to 168 min. Nordberg et al measured plasma concentrations of pethidine after both intrathecal (25 mg) and epidural (100 mg) injection and showed that systemic absorption of pethidine was slower after intrathecal injection (t max 2.3±1.8 h) compared with epidural injection (t max 0.23±0.03 h) but overall systemic bioavailability was similar 21 .
After intrathecal injection of pethidine, maximum concentrations of pethidine in CSF were measured at 5-10 min after injection 21, 22 . Nordberg et al measured CSF and plasma concentrations of pethidine after intrathecal injection of 25 mg of pethidine and found that the maximum CSF/plasma concentration ratio was 6000:45,000 21 . This compared with a ratio of 26:97 after epidural injection. The volume of distribution in CSF was 13±13 ml. Sjöström et al measured concentrations of pethidine and morphine in CSF after intrathecal injection 22 . Maximum concentrations in CSF of both drugs were considerably higher than concentrations in plasma. Pethidine disappeared from CSF faster than morphine which was attributed to the greater lipid solubility of pethidine. After 6 h, a smaller percentage of the dose of pethidine (0.4%) remained in lumbar CSF compared with morphine (1.6%). The faster elimination of pethidine from CSF compared with morphine suggested that there was a higher risk of cephalad spread after intrathecal injection with morphine.
Maurette et al measured concentrations of pethidine in plasma and ventricular CSF in head-injured patients after intrathecal injection of pethidine 1 mg/kg 17 . Pethidine was detected in CSF within one hour of injection and maximum concentrations in CSF were one-third to one-fifth that found in plasma. Based on the early appearance of pethidine in ventricular CSF and the similarity of the concentration-time curves for pethidine in ventricular CSF and plasma, they concluded that the potential risk of respiratory depression was related mainly to absorption of pethidine into the systemic circulation and redistribution back into ventricular CSF.
To date, no studies have specifically investigated the risk of neurotoxicity of intrathecal pethidine. The large number of reported cases of the use of intrathecal pethidine without documented neurological complications has been cited as evidence for its safety 23, 24 and the conduction block induced by pethidine has been shown in vitro to be reversible 6 .
CLINICAL EXPERIENCE 1. Spinal Anaesthesia
In the first report of spinal anaesthesia using pethidine, Mircea et al described a large series of 713 patients who received intrathecal pethidine in doses ranging from 0.8 to 1 mg/kg or fixed doses of 50 mg or 75 mg for abdominal, perineal and lower limb surgery 5 . Numerous other reports followed and have described the use of intrathecal pethidine for anaesthesia for a variety of surgical procedures, including surgery on the lower limb and hip 5,25-30 , perineal and urological surgery 5, 16, 18, [30] [31] [32] [33] [34] [35] [36] , lower abdominal surgery 5, 25, 30, 37 and caesarean section 24, [38] [39] [40] [41] [42] .
Dosage
Doses of pethidine used for spinal anaesthesia have ranged from 0.5 to 1 mg/kg as well as fixed doses of 50 mg, 60 mg and 100 mg. Because of variation in patient populations, positioning during injection and additives used, a wide range of clinical responses to different doses have been reported. Reports in the English language are summarized in Table 2 . A dose of 1 mg/kg has been adequate for lower limb, hip, urological, perineal, and lower abdominal surgery including caesarean section. Fixed doses of 60 mg (mean dose 0.79 mg/kg) and 100 mg (mean dose 1.77 mg/kg) have been used for lower limb and lower abdominal surgery. Lower doses of 0.5 mg/kg were sufficient for lower limb, hip, perineal and endoscopic urological surgery and have generally been associated with fewer side-effects compared with the higher doses 26, 27, 33 .
Few studies have directly compared different doses of intrathecal pethidine. Nguyen Thi et al investigated addition of pethidine in doses of 0.05 to 0.5 mg/kg to 10 mg hyperbaric bupivacaine 0.5% in patients having lower limb surgery 23 . There was no correlation between the dose of pethidine and the duration of sensory block but pethidine caused a dose-related increase in postoperative analgesia and a dose-related increase in the duration of motor block. Grace and Fee compared intrathecal pethidine 0.5 mg/kg with 0.75 mg/kg in patients having transurethral resection of the prostate gland 35 . With the 0.75 mg/kg dose, the median duration of sensory block was greater (150 vs 120 min) and the median duration of motor block was greater (105 vs 80 min) compared with the 0.5 mg/kg dose, but these differences were not considered clinically significant. There was no difference between the two doses in the quality of intraoperative anaesthesia or the incidence of side-effects and postoperative analgesia.
Baricity and patient positioning
Pethidine has the properties of a hyperbaric agent when injected intrathecally 5 . Therefore, the spread of anaesthesia can be influenced by the position of the patient during and immediately after intrathecal injection. Acalovschi et al described saddle block for perineal surgery using intrathecal pethidine 0.5 mg/kg 43 . By injecting the dose with the patient sitting and maintaining this position for five minutes before placing the patient supine, sensory block was limited to the S2-5 dermatomes and permitted early ambulation. Similarly, Patel et al maintained patients having endoscopic urological procedures in the sitting position for ten minutes after intrathecal injection of pethidine 0.5 mg/kg 33 . In this study, the spread of sensory block was somewhat greater, with the highest dermatomal levels achieved ranging from T8-T11. Part of the difference in spread might be explained by differences in the age of the patients studied (mean age 37 years in the study by Acalovschi et al compared with 69 years in the study by Patel et al).
Because pethidine has moderately high lipid solubility, it diffuses rapidly into lipid-rich areas of the spinal cord which reduces its propensity for cephalad migration in CSF 44 . However, a certain amount of time is required for pethidine to "fix". Thus in studies where patients were immediately placed supine after intrathecal injection of pethidine in the lower dose ranges with the patient sitting, relatively high spread of the block has been described 31, 34, 35 .
When pethidine has been injected intrathecally in doses greater than 0.5 mg/kg, relatively high blocks have been described, despite maintaining patients in the sitting position for variable periods after injection; however blocks have generally been lower than those achieved when injection was performed with the patient lateral ( Table 2) .
Additives and mixtures
A number of substances have been added to intrathecal pethidine which can potentially alter the quality of anaesthesia. Dextrose, which is commonly added to increase the baricity of local anaesthetics, was added to pethidine 1 mg/kg by Cozian et al 32 
and
Talafre et al 38 . However, as the standard preparation of pethidine has been shown to behave as a hyperbaric solution, addition of dextrose may not significantly affect the spread and disposition of pethidine in CSF. Accordingly, the characteristics of the block attained in the studies where dextrose has been added 140 W. D. NGAN KEE Anaesthesia and Intensive Care, Vol. 26, No. 2, April 1998 have been similar to those in studies where plain solution was used ( Table 2 ). In the majority of reports of spinal anaesthesia using pethidine, the undiluted solution which has a concentration of 50 mg/ml has been used. However, Grace and Fee added saline to pethidine 0.5 and 0.75 mg/ml to increase the total injectate volume to 4 ml 35 . The level of the block that resulted from the dose of 0.5 mg/kg was the highest that has been reported from this dose. Further investigation using standardized patient positioning and speed and site of injection are required to determine the effect of injectate volume on the characteristic of the block from intrathecal pethidine. In another study, Grace et al added clonidine 75 µg to pethidine 0.75 mg/kg given intrathecally to patients having total hip joint replacement 45 . The characteristics of the spinal block were similar to those in other reports, and there was no improvement in postoperative analgesia compared with a control group that received bupivacaine 0.5%. However, the pethidine-clonidine group had a greater incidence of hypotension and the authors concluded that this mixture did not have advantages over bupivacaine.
Substances have been added to intrathecal pethidine in attempts to prolong the duration of spinal anaesthesia. Bostrom et al reported that the addition of adrenaline 200 µg to pethidine 0.5 mg/kg in patients having endoscopic urological surgery did not prolong the duration of sensory block compared with controls 46 . Onset time and the incidence of complications were similar between groups although more patients in the control group had complete motor block. Langerman et al found that the duration of analgesia and motor block were prolonged in rabbits when intrathecal pethidine was dissolved in a lipid solution compared with the standard aqueous solution 47 . They attributed this finding to slow release of pethidine from the lipid phase that effectively served as a depot of drug in the CSF. Further investigation of drug formulations based on lipid vehicles was suggested.
Several reports have investigated mixtures of pethidine with local anaesthetics for spinal anaesthesia. Addition of pethidine in doses of 0.05 to 0.5 mg/kg to 10 mg hyperbaric bupivacaine 0.5% by Nguyen Thi et al 23 was described above. Tzeng et al reported that addition of pethidine 0.25 mg/kg to tetracaine 10 mg increased the speed of onset and duration of sensory and motor block and improved postoperative analgesia, but this was at the cost of increased cardiovascular depression, compared with tetracaine alone 48 .
Conway et al compared haemodynamic effects of pethidine 0.4 mg/kg plus hyperbaric bupivacaine 7.5 mg with pethidine 0.8 mg/kg and bupivacaine 15 mg 29 . All groups produced similar reductions in arterial pressure, systemic vascular resistance and central venous pressure but there was a high incidence of bradycardia in both groups that received pethidine that was not seen with bupivacaine. Tauzin-Fin et al found that addition of prilocaine 0.5 mg/kg to intrathecal pethidine 1 mg/kg resulted in faster onset and longer duration of block but enhanced the systemic absorption of pethidine 18 . Maurette et al compared lignocaine 1.6% with lignocaine 1.6% plus pethidine 1% for continuous spinal anaesthesia in patients having surgery for fracture of the neck of the femur 49 . Addition of pethidine reduced the initial dose requirement for lignocaine and improved postoperative analgesia. However, the mixture group had a high incidence of drowsiness and greater haemodynamic instability and the authors did not recommend the use of this combination in the doses used. Chen et al reported that addition of pethidine 0.2 mg/kg reduced the incidence of shivering from 56.7% to 16.7% when added to tetracaine 12-16 mg used for spinal anaesthesia 50 .
Postoperative analgesia
A potential advantage that pethidine has over conventional local anaesthetics as an agent for spinal anaesthesia is its dual properties of being a both a local anaesthetic and an opioid receptor agonist. The opioid effects may persist into the postoperative period and several studies have shown that postoperative pain and analgesic requirement were reduced in patients who had lower abdominal and lower limb surgery under spinal anaesthesia using pethidine compared with conventional local anaesthetics. Talafre et al found that patients who received intrathecal pethidine for caesarean section required less intramuscular pethidine for postoperative analgesia in the first 12 h after surgery compared with patients who received tetracaine 38 . Kafle 39 and Norris et al 37 compared intrathecal pethidine with lignocaine for caesarean section and postpartum sterilization respectively. In both studies, the mean duration of postoperative analgesia was greater in patients who received pethidine (6 h vs 1h and 448 min vs 83 min). Sangarlangkarn et al also compared intrathecal pethidine with lignocaine for lower abdominal and lower limb surgery and found more patients in the pethidine group required only oral analgesia in the first 24 h postoperatively, although the number of patients who were pain-free and required no analgesia was similar between groups 25 . Nguyen Thi et al showed a dose-related increase in postoperative analgesia after lower limb surgery occurred when pethidine 0.05 to 0.5 mg/kg was added to intrathecal bupivacaine 0.5% 23 .
In contrast, studies that have compared intrathecal pethidine with conventional local anaesthetics for endoscopic urological surgery have not shown a difference in postoperative pain or analgesic requirement. This may be related to there being less postoperative pain associated with these procedures. Furthermore, Grace et al compared intrathecal pethidine 0.75 mg/kg plus clonidine 75 µg with bupivacaine 13.75 mg and bupivacaine 13.75 mg plus morphine 0.5 mg for total hip joint replacement 45 . They found that 24h postoperative analgesic requirement in the pethidine-clonidine group was similar to that in the bupivacaine group and significantly more than that in the bupivacaine-morphine group. They concluded that the postoperative analgesic effects of intrathecal pethidine are relatively short-lived.
Investigations of the addition of pethidine to conventional local anaesthetic for spinal anaesthesia for caesarean section have shown that early postoperative analgesia is improved. Feldman et al found that addition of pethidine 10 mg to bupivacine 12 mg resulted in lower pain scores and reduced requirement for supplementary analgesia at 2 h compared with saline control 51 . Increasing the dose of pethidine to 20 mg caused more side-effects without improving analgesia. A subsequent study from the same centre showed that a combination of pethidine 10 mg with morphine 0.15 mg added to intrathecal bupivacaine resulted in better early postoperative analgesia compared with morphine alone or fentanyl 52 .
Analgesia In Labour
The introduction of small-gauge, atraumatic spinal needles, microcatheters and combined spinalepidural techniques has increased the popularity of intrathecal opioids in labour. Advantages of this technique include rapid onset of analgesia and preservation of motor function 53 . A variety of different drugs have been used, alone and in combination with local anaesthetics. The efficacy of intrathecal pethidine for analgesia was investigated by Norris et al 54 and Swayze et al 55 . In both these studies, intrathecal pethidine 10 mg was injected via spinal microcatheters. Norris et al found that eight of 10 parturients obtained dramatic reduction in pain within five minutes, although two patients required a second dose to obtain adequate pain relief 54 . One patient developed pruritus, two patients vomited and two patients required ephedrine for treatment of hypotension. Swayze et al administered a bolus of intrathecal pethidine 10 mg to 20 parturients at their first request for analgesia with subsequent doses of 7 mg as required 55 . Effective analgesia with high level of patient satisfaction was obtained with a mean pethidine consumption of 12.96 mg/hr. Following the initial dose, mean onset time for analgesia was 3.9 min (range 2 to 12 min) and mean duration of 83 min (range 38 to 120 min). No patients developed hypotension, and only two patients (10%) developed slight motor block. Eight patients (40%) complained of nausea, three (15%) had pruritus and two (10%) became drowsy. In five cases a transient fetal bradycardia was noted, two within 15 min of a dose of pethidine, but none required operative delivery and there were no adverse fetal outcomes. Plasma concentrations of pethidine in maternal and umbilical cord blood ranged widely with maximum recorded values of 250.4 and 157.5 ng/ml respectively. Honet et al also used a spinal catheter technique in a comparison of intrathecal pethidine, fentanyl and sufentanil for analgesia in labour 56 . They found that the drugs gave similar onset and duration of analgesia but patients receiving pethidine had lower pain scores once cervical dilatation progressed beyond 6 cm. The incidence of side-effects in all groups was low, but patients receiving pethidine experienced more nausea. In a review of complications of epidural and combined spinal-epidural analgesia in labour, Norris et al found patients who received intrathecal pethidine had less pruritus but more frequent nausea and hypotension compared with patients who received sufentanil 57 .
Adverse effects
Although the use of intrathecal pethidine has been recommended to reduce the risk of haemodynamic fluctuations in high risk patients 58 , analysis of reports of its use indicates that pethidine can cause haemodynamic instability that is equal to or greater than that associated with conventional local anaesthetic drugs 38, 59 . Furthermore, intrathecal pethidine is associated with a number of other adverse effects (Table 3) . However, the incidence of side-effects is less when the dose is limited to 0.5 mg/kg. Following a dose of 0.5 mg/kg, the reported incidence of hypotension ranged from 0 to 17% compared with an incidence of 3.3 to 64% in doses of 0.75 mg/kg and greater.
The haemodynamic changes associated with intrathecal pethidine were examined in detail by Cozian et al 32 and Conway et al 29 . Cozian et al found intrathecal pethidine 1 mg/kg caused reductions in mean arterial pressure, right atrial pressure, mean pulmonary artery pressure and pulmonary capillary wedge pressure 32 . Cardiac index was unchanged and there was a small reduction in systemic vascular resistance index. The changes in mean arterial pressure correlated with changes in systemic vascular resistance index. There was a small decrease in heart rate, and although the change was not statistically significant, it was considered clinically significant since the reduction in arterial pressure would normally be expected to cause a baroreceptor-mediated increase in heart rate. Bradycardia after intrathecal pethidine has been observed in a number of other reports. Conway et al reported that bradycardia requiring atropine occurred in six of 14 (43%) elderly patients who received pethidine 0.8 mg/kg for urological surgery and four of 14 (29%) who received a mixture of pethidine 0.4 mg/kg plus bupivacaine 7.5 mg 29 . Patients in that study did not receive intravenous fluid preload and bradycardia only occurred when the upper level of the block was T7 or higher. The incidence of bradycardia in other reports has ranged from 0 to 20% (Table 3 ). Shimai and Yokohama reported atrioventicular block that occurred after a young patient who received intrathecal pethidine 45 mg had bradycardia treated with intravenous atropine 60 .
Other adverse effects that are associated with intrathecal pethidine include nausea and vomiting, pruritus, sedation and respiratory depression. Several comparative studies have shown that the incidence of these side-effects is greater with pethidine compared with conventional local anaesthetics although this may be dose-dependent 25, 29, 37, 39 . In the first report of spinal anaesthesia using pethidine, Mircea et al described a syndrome of hypotension, bradycardia and hypoxaemia that occurred in 0.55% of patients 5 . Subsequently, the incidence of these adverse effects has varied considerably between studies although the incidence appears greater with doses greater than 0.5 mg/kg. Treatment of these side-effects responds to standard methods although amelioration of pruritus associated with intrathecal pethidine using low-dose propofol has been described 61 . Reactivation of herpes simplex type I after intrathecal pethidine has been reported although other factors may also have been contributory in this case 62 .
Sedation after intrathecal pethidine has been reported frequently and there have been some reports of respiratory depression which may be doserelated 5 . Several patients in the initial report by Mircea et al required assisted ventilation and the authors recommended that the dose of pethidine should not exceed 1 mg/kg 5 . Andrivet et al reported that two of 10 patients who received intrathecal pethidine 1 mg/kg for orthopaedic surgery developed respiratory depression and required treatment with naloxone 63 . Sangarlangkarn et al gave a fixed dose of pethidine 100 mg intrathecally that was equivalent to a mean dose of 1.8 mg/kg and found that one patient required assisted ventilation 25 31 1 mg/kg 15% 20% 30% 25% Cozian 32 1 mg/kg ns ns 12.5% 62.5% Naguib 16 1 mg/kg 20% 20% nil 60% Talafre 38 1 mg/kg 50% ns 40% 38% Spiers 28 1 mg/kg ns ns ns ns Tauzin-Fin 18 1 mg/kg 1 (3.3%) nil nil nil Lewis 34 1 mg/kg 10% 3.3% 6.7% 13.3% Kafle 39 1 mg/kg 32% 0 8% 32% Nguyen Thi 24 1 mg/kg 36% 0 32% 10.7% Grace 35 0.75 mg/kg 5% ns 10% 35% Grace 35 0.5 mg/kg 4.8% ns 15% 15% Conway 29 0.8 mg/kg 9 (64%) 6 (42.8%) 6 (42.8%) nil Sangarlangkarn 25 100 mg 2 (10%) ns 55% 10% Norris 37 60 mg ns ns ns ns Acalovschi 43 0.5 mg/kg nil nil 4.5% 6.3% Kavuri 26 0.5 mg/kg 17% ns 0 33% Patel 33 0.5 mg/kg 14% ns 0 4.5% Trivedi 27 0.5 mg/kg 0 0 6.3% 6.3% ns=not specified reported respiratory depression in two patients who received a fixed dose of 50 mg 64 . The first patient was an 81-year-old woman who weighed 73 kg and who had received premedication of diazepam 10 mg. She had an upper sensory level of T8 and required naloxone. The second patient was a 24-year-old woman who weighed 70 kg who became hypoxaemic and required oxygen and verbal stimulation in the recovery room. She had received midazolam 2 mg intraoperatively. Brownridge et al reported a 24-yearold parturient who required assisted ventilation and naloxone after accidental intrathecal injection of pethidine 50 mg in 10 ml saline injected through an epidural catheter that was subsequently shown radiologically to be in the subarachnoid place 65 . Delayed respiratory depression after intrathecal pethidine has not been reported.
Cost and availability
Intrathecal pethidine may have advantages when cost and availability are considered. In the author's institution, the cost of a single dose of pethidine is 13 to 14 times less than the equivalent cost for the standard preparations of bupivacaine. In addition, pethidine provides an alternative in developing countries when local anaesthetics are not available 24, 66 . Intrathecal pethidine can also be considered in the presence of allergy to conventional local anaesthetic drug 41, 67 .
CONCLUSIONS
Pethidine is unique amongst the opioids in possessing local anaesthetic activity sufficient for its use as sole agent for spinal anaesthesia. Intrathecal pethidine is effective for providing spinal anaesthesia for endoscopic urological procedures and surgery of the lower limb, perineum and lower abdomen including caesarean section. The combination of opioid and local anaesthetic activity confers the ability to provide surgical anaesthesia that is comparable to that achieved with conventional local anaesthetic agents and early postoperative analgesia that may be superior. In low doses, intrathecal pethidine provides effective analgesia in the first stage of labour and is more effective than intrathecal fentanyl and sufentanil as labour advances. However, the incidence of side-effects is greater with pethidine compared with the other commonly used intrathecal opioids.
Adverse effects that have been reported after intrathecal pethidine include hypotension, bradycardia, sedation, respiratory depression, nausea and pruritus. The risk of these occurring increases with dose. Respiratory depression should be treated with assisted ventilation and naloxone. Other side-effects should be managed as for conventional spinal anaesthesia. Pethidine appears to have a therapeutic index that is lower than that of conventional local anaesthetics used for spinal anaesthesia, particularly for doses of 1 mg/kg or greater. In order to minimize side-effects, the dose should be limited to 0.5 mg/kg for perineal procedures and 0.5 to 1.0 mg/kg for lower limb and lower abdominal procedures. Because pethidine behaves like a hyperbaric agent, patient posture can be manipulated to control spread of spinal block. Undiluted pethidine in a concentration of 50 mg/ml is effective for spinal anaesthesia. Increasing injectate volume may increase the extent of the block. There is no evidence that addition of dextrose or adrenaline has significant advantages. Careful postoperative monitoring is mandatory with the use of intrathecal pethidine and concurrent use of sedatives should be avoided.
With the current techniques, intrathecal pethidine has not been established as a first-line agent for routine use. However it has the advantage of being inexpensive and it is a good alternative for patients with allergy to amino-linked and ester-linked local anaesthetics or in developing countries where these drugs are not available or resources are limited. With controversy currently surrounding the use of lignocaine for spinal anaesthesia 68 there is a need for alternative short-acting spinal anaesthetic agents. Further investigation is warranted to determine whether pethidine can fill this gap.
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